Imexpharm Corporation reported VND2,205 billion (US$87.3 million) in net revenue for 2024, marking a 10.6% year-on-year ...

Venus Remedies has secured the renewal of its EU-GMP certification from Infarmed, Portugal, for its Cephalosporin, Carbapenem ...

Canadian shares may open flat or with a slightly negative bias on Thursday, tracking weak crude oil prices and amid concerns about ...

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces today the launch of the company's first German-cultivated medical cannabis product, ...

The certification covers the company’s manufacturing facility for cephalosporin, carbapenem, and lyophilized injectable ...

Imexpharm Corporation has announced its 2024 financial results with net revenue reaching VND2,205 billion, up 10.6 percent year on year, driven by robust growth in ETC channel and high-quality ...

Venues remedies rallied 5.30% to Rs 310.95 after the company successfully renewed its European good manufacturing practices (GMP) certification by infarmed, the national health authority of Medicines ...

Decibel Cannabis Company Inc. (the "Company" or "Decibel") (TSXV: DB) (OTCQB: DBCCF), a market leader in premium cannabis and ...

HYTN will endeavour to amend its licenses and/or certificates, establish a stability program, and implement GMP-compliant processes tailored for vape cartridge production.

EQS-News: SynBiotic SE / Key word (s): Mergers & Acquisitions/Strategic Company Decision SYNBIOTIC with four new investments in 2024: Further acquisitions in sight for 2025 10.01.2025 / 11:44 ...